Active	Status	Sponsor type	Region	Phase	Filter
4 Active 0 Inactive 4 All	Not yet recruiting Recruiting Enrolling by invitation Active, not recruiting Available No longer recruiting	Industry lead sponsor Industry collaborator Coop Other	US Canada Japan Europe RoW	N/A 1 2 3 4	Highlight changes:- Show only changed items Enrollment:

Advanced Filters

4 Trials

Active Trials   

 

Export

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
Widt-Levert, De
LORD, NCT02492607: Management of Low-risk (Grade I and II) DCIS	Recruiting	N/A	2500	Europe	Standard treatment, digital mammography, Active surveillance, radiotherapy	The Netherlands Cancer Institute, Borstkanker Onderzoek Groep, European Organisation for Research and Treatment of Cancer - EORTC	DCIS	02/34	02/34
Custers, Frank LJ
MATINEE, NCT04133909 / 2018-001540-56: Mepolizumab as Add-on Treatment IN Participants With COPD Characterized by Frequent Exacerbations and Eosinophil Level Jan 2024 - Dec 2024: Acceptance of regulatory submission in US (based on MATINEE trial) for COPD Jan 2024 - Dec 2024: Acceptance of regulatory submission in EU (based on MATINEE trial) for COPD Jan 2024 - Dec 2024: Data from MATINEE trial for COPD Jan 2024 - Dec 2024: Acceptance of regulatory submission in China (based on MATINEE trial) for COPD Jan 2024 - Dec 2024: Acceptance of regulatory submission in Japan (based on MATINEE trial) for COPD	Active, not recruiting	3	806	Europe, Canada, Japan, US, RoW	Placebo, Mepolizumab	GlaxoSmithKline, PPD	Pulmonary Disease, Chronic Obstructive	08/24	08/24
PRECISION, NCT05854901: PCT-guided Treatment Regarding Antibiotic Use for Acute COPD Exacerbations	Recruiting	N/A	693	Europe	Procalcitonin, PCT, Physician's decision	Erasmus Medical Center, ZonMw: The Netherlands Organisation for Health Research and Development	COPD Exacerbation, COPD, Acute Copd Exacerbation	02/25	02/25
Vissers, Y
LORD, NCT02492607: Management of Low-risk (Grade I and II) DCIS	Recruiting	N/A	2500	Europe	Standard treatment, digital mammography, Active surveillance, radiotherapy	The Netherlands Cancer Institute, Borstkanker Onderzoek Groep, European Organisation for Research and Treatment of Cancer - EORTC	DCIS	02/34	02/34